Drug Profile


Alternative Names: AMG-103; Anti-CD19 BiTE antibody; Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody; Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody; Blincyto; MEDI-538; MT-103

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Micromet Inc
  • Developer Amgen; Astellas Pharma; M. D. Anderson Cancer Center; Micromet Inc; National Cancer Institute (USA); University of California, Davis
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; B cell prolymphocytic leukaemia; Acute lymphoblastic leukaemia; B cell lymphoma; T cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Hairy cell leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia
  • Phase II/III Non-Hodgkin's lymphoma
  • Phase II Diffuse large B cell lymphoma
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 05 Oct 2017 Amgen plans a phase II trial for Large B-cell lymphoma (NCT03298412)
  • 18 Sep 2017 Phase-I clinical trials in Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in Italy, France (IV) (NCT02961881)
  • 18 Sep 2017 Amgen initiates enrolment in a phase I trial in Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in USA (IV) (NCT02961881)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top